TickerTalks
Browse all tickers →
TickerTalks›$EYPT
EYEYPT

EyePoint Pharmaceuticals, Inc.

$EYPT·$285M·Biotechnology·Healthcare
$3.07-7.5%YTD-83.3%1Y-77.0%
Price updated 13h ago·X counts updated 3d ago
EYEYPT
$EYPTEyePoint Pharmaceuticals, Inc.
$3.07-7.53%13 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $EYPT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

13X posts · last 7 days
Sep 28Oct 11
Bearish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-09-09

TD Cowen downgraded EyePoint from Buy to Hold and cut its price target to $4 from $20 after the Phase III LUGANO miss reduced the firm's confidence in the wAMD approval path. Cowen's follow-on note explicitly recommended selling $EYPT and buying $OCUL instead.

Read what X is saying about $EYPT

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $EYPT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storySelling offAI verdict · as of 2026-10-03

Falling on heavy selling — points lower unless it turns around.

EyePoint down 82% YTD with LUGANO Phase III miss and TD Cowen downgrade — a specific broken-biotech setup.

EyePoint Pharmaceuticals is a specialty-ophthalmology biopharma whose 2026 drawdown reflects a specific Phase III failure plus coordinated sell-side downgrades.

  • The P&L is pre-commercial-at-scale: Q2 revenue was $507K (down 90.5% YoY from a very small base) at a -19,207% operating margin and EPS of -$1.09, with trailing EPS prints missing Street estimates by 7.9% and 25.3% — these are the numbers of a company whose revenue trajectory has fallen apart.
  • The specific catalyst is explicitly bearish: TD Cowen downgraded EyePoint from Buy to Hold with PT cut to $4 from $20 after the Phase III LUGANO miss reduced confidence in the wAMD approval path — plus Cowen explicitly recommended selling EYPT and buying OCUL instead.

At 1% of its 52-week range and 74% below the 200-day going into Nov 4 earnings, this is a textbook broken-biotech setup. A specific LUGANO-pathway-reset announcement or any strategic transaction is the trigger for a potential reversal; another cash-burn surprise without clean regulatory pathway is the invalidation.

Agrees with X sentimentThe TD Cowen downgrade with specific $4 PT and explicit sell-EYPT/buy-OCUL framing is grounded on specific sell-side action. The Pomerantz investigations are standard post-drawdown boilerplate.

What to watch: Nov 4 Q3 earnings — LUGANO regulatory-pathway commentary, cash runway, pipeline-reset announcements, and any strategic transaction. Named regulatory reset is the trigger; another cash-burn surprise is the invalidation.

On the calendar: 2026-11-04 — Q3 earnings

event ahead 30dtrial failure

Read the AI verdict on $EYPT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

EyePoint Pharmaceuticals develops sustained-release implantable drug delivery systems for retinal diseases including wet AMD and diabetic macular edema.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $EYPT.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $EYPT

Neutral — EyePoint Pharmaceuticals develops sustained-release implantable drug delivery systems for retinal diseases including wet AMD and diabetic macular edema.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+32.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-168%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-114%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-60.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
159.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-136%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
41.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-1.09$-1.01-7.9%
Q1 2026May 6, 2026$-0.99$-0.79-25.3%
Q4 2025Mar 4, 2026$-0.81$-0.78-3.8%
Q3 2025Nov 5, 2025$-0.85$-0.77-10.4%
Next earningsWed, Nov 4·consensus EPS $-0.91

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$507K-90.5%100%-19207%$-1.09$-63.5M
Q1 FY26$696K-97.2%24.1%-12532%$-0.99$-81.5M
Q4 FY25$620K-94.6%39.5%-11346%$-0.81$-66.0M
Q3 FY25$966K-90.8%25.4%-6421%$-0.85$-60.2M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.7M$1.6M – $2.1M-$3.72-$4.13 – -$2.9710
FY27$17.9M$6.1M – $29.7M-$2.73-$4.18 – -$1.229
FY28$196.3M$123.0M – $295.2M-$1.63-$3.68 – $0.889
FY29$437.4M$274.0M – $657.7M$0.11$0.06 – $0.184
FY30$621.9M$389.7M – $935.2M$1.30$0.67 – $2.164

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.0%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-46.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-74.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 70.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.685-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyAug 18Karen L. ZaderejDirector10.6K sh$52KSellJun 30Ramiro RibeiroChief Medical Officer4.9K sh$73KSellApr 17Ramiro RibeiroChief Medical Officer2.4K sh$37K
+ 8 other (4 exempts · 2 inkinds · 1 other · 1 gift) in window

See when $EYPT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 178-K — Item 1.01: Material agreement
AI summary

EyePoint, Inc. (EYPT) entered into a settlement agreement with the U.S. Department of Justice (DOJ) on July 17, 2026, acting on behalf of the Office of Inspector General of HHS and the Defense Health Agency (TRICARE Program), to resolve potential civil claims under the False Claims Act, Civil Monetary Penalties Law, and Administrative False Claims Act. Settlement terms and financial amounts are not visible in the excerpt. A DOJ/HHS False Claims Act settlement is a material legal event for EyePoint, likely relating to prior marketing or reimbursement practices; the settlement amount and any exclusion risks are key details requiring the full filing.

8-KOfficer or director changeJun 228-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
+ 20 other (9 13Gs · 4 routine 8-Ks · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTglobenewswire.com·8d agoContrasting Eyepoint Pharmaceuticals (NASDAQ:EYPT) & GSK (NYSE:GSK)defenseworld.net·10d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTprnewswire.com·13d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTglobenewswire.com·15d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTprnewswire.com·20d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $EYPT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport